News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
AMATSI (Formerly CRID Pharma) and AVOGADRO Combine Strengths to Become the French Leader in Drug Development Services
February 28, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MONTPELLIER, France--(BUSINESS WIRE)--AMATSI (formerly known as CRID Pharma) and AVOGADRO, two contract drug development organizations, have today announced that they will combine to become the French leader in this sector.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Europe
MORE ON THIS TOPIC
Autoimmune disease
Cullinan Bets $700M+ in Back-Heavy China Deal for Autoimmune T Cell Engager
June 5, 2025
·
2 min read
·
Tristan Manalac
Layoff Tracker
Rapt Shrinks Again After Dumping Asthma, Atopic Dermatitis Drug
June 5, 2025
·
219 min read
·
BioSpace Editorial Staff
Obesity
Lilly Inks Deal Worth up to $870M To Develop Long-Acting GLP-1 Obesity Drugs
June 4, 2025
·
2 min read
·
Nick Paul Taylor
Business
Opinion: Investing in Research and Welcoming Global Talent Strengthens America
June 4, 2025
·
4 min read
·
Dr. Chris Otiko